Showing results (71-80 of 216) with videos related to

Sort By:
Pageof 22
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 23, 2014
Second autologous stem cell transplant: an effective therapy for relapsed multiple myelomaKamal Kant Singh Abbi, Junting Zheng, Sean M Devlin, et al.
Statistics in Medicine|May 19, 2025
Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non-InferiorityHakim-Moulay Dehbi, Sean Devlins, Alexia Iasonos, et al.
Tissue Engineering. Part A|July 10, 2018
A Bilayered Poly (Lactic-Co-Glycolic Acid) Scaffold Provides Differential Cues for the Differentiation of Dental Pulp Stem CellsRiddhi A Gangolli, Sean M Devlin, Jonathan A Gerstenhaber, et al.
Statistics in Medicine|April 20, 2016
Dimension of model parameter space and operating characteristics in adaptive dose-finding studiesAlexia Iasonos, Nolan A Wages, Mark R Conaway, et al.
The American Journal of Managed Care|May 13, 2008
Complementary and alternative medicine provider use and expenditures by cancer treatment phaseWilliam E Lafferty, Patrick T Tyree, Sean M Devlin, et al.
Leukemia Research|February 27, 2018
Widespread use of measurable residual disease in acute myeloid leukemia practiceZachary D Epstein-Peterson, Sean M Devlin, Eytan M Stein, et al.
Alcoholism, Clinical and Experimental Research|April 25, 2012
Trajectory analyses in alcohol treatment researchJinsong Chen, Bankole A Johnson, Xin-Qun Wang, et al.
Health and Quality of Life Outcomes|August 9, 2007
Quality of life at the end of lifePaula Diehr, William E Lafferty, Donald L Patrick, et al.
Annals of Hematology|August 21, 2016
Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemiaSamantha N Reiss, Larry W Buie, Nelly Adel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2012
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trialsAlexia Iasonos, Mrinal Gounder, David R Spriggs, et al.
Pageof 22